Melanoma Research Laboratory and Department of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia.
Mol Oncol. 2010 Oct;4(5):451-7. doi: 10.1016/j.molonc.2010.06.006. Epub 2010 Jun 23.
Melanoma, like most cancers, is a disease that wreaks havoc mostly through its propensity to spread and establish secondary tumors at sites that are anatomically distant from the primary tumor. The consideration of models of cancer progression is therefore important to understand the essence of this disease. Previous work has suggested that melanoma may propagate according to a cancer stem cell (CSC) model in which rare tumorigenic and bulk non-tumorigenic cells are organized into stable hierarchies within tumors. However, recent studies using assays that are more permissive for revealing tumorigenic potential indicate that it will not be possible to cure patients by focusing research and therapy on rare populations of cells within melanoma tumors. Studies of the nature of tumorigenic melanoma cells reveal that these cells may gain a growth, metastasis and/or therapy resistance advantage by acquiring new genetic mutations and by reversible epigenetic mechanisms. In this light, efforts to link the phenotypes, genotypes and epigenotypes of melanoma cells with differences in their in vivo malignant potential provide the greatest hope of advancing the exciting progress finally being made against this disease.
黑色素瘤与大多数癌症一样,主要通过其扩散倾向和在与原发性肿瘤解剖学上相距较远的部位建立继发性肿瘤的能力对人体造成严重破坏。因此,考虑癌症进展模型对于理解这种疾病的本质很重要。先前的研究表明,黑色素瘤可能根据癌症干细胞 (CSC) 模型进行传播,在该模型中,罕见的肿瘤发生和大量非肿瘤发生细胞在肿瘤内组织成稳定的层次结构。然而,最近使用更有利于揭示肿瘤发生潜能的检测方法的研究表明,通过将研究和治疗集中在黑色素瘤肿瘤内的少数细胞群上,不可能治愈患者。对肿瘤发生性黑色素瘤细胞性质的研究表明,这些细胞可能通过获得新的遗传突变和可逆的表观遗传机制获得生长、转移和/或治疗耐药性优势。有鉴于此,努力将黑色素瘤细胞的表型、基因型和表观基因型与其体内恶性潜能的差异联系起来,为对抗这种疾病所取得的令人兴奋的进展提供了最大的希望。